Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors 1 1Edited by J. Karn
- 1 September 2001
- journal article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 312 (4) , 795-805
- https://doi.org/10.1006/jmbi.2001.4988
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patientsInternational Journal of STD & AIDS, 1998
- Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patientsAIDS, 1996
- L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1995
- Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strainsAntiviral Research, 1995
- Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsNature Structural & Molecular Biology, 1995
- Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside InhibitorsScience, 1995
- HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and TherapyScience, 1995
- Characterization of HIV-1 Strains Isolated from Patients Treated with TIBO R82913AIDS Research and Human Retroviruses, 1994
- Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsAntimicrobial Agents and Chemotherapy, 1993
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences, 1991